<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04746963</url>
  </required_header>
  <id_info>
    <org_study_id>AXT107-CS102</org_study_id>
    <nct_id>NCT04746963</nct_id>
  </id_info>
  <brief_title>Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration</brief_title>
  <acronym>SHASTA</acronym>
  <official_title>Phase 1/2a Study of the Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AsclepiX Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AsclepiX Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, dose-escalating, 48-week study assessing the safety, tolerability,&#xD;
      bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or&#xD;
      0.5 mg AXT107 in approximately 18 subjects (up to 6 subjects per dose) with nAMD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as Assessed by Incidence of Adverse Events (AEs)</measure>
    <time_frame>Screening to Week 48</time_frame>
    <description>Incidence of ocular (study eye) and systemic AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as Assessed by Central Retinal Thickness (CST)</measure>
    <time_frame>Day 0 to Week 48</time_frame>
    <description>Mean change in CST assessed by spectral domain optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as Assessed by Early Treatment Diabetic Retinopathy Study (EDTRS) Chart</measure>
    <time_frame>Day 0 to Week 48</time_frame>
    <description>Mean change in Best Corrected Visual Acuity (BCVA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as Assessed by Early Treatment Diabetic Retinopathy Study (EDTRS) Chart</measure>
    <time_frame>Day 0 to Week 48</time_frame>
    <description>Percentage of subjects improving ≥5, ≥10, and ≥15 letters in Best Corrected Visual Acuity (BCVA)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Neovascular Age-Related Macular Degeneration (nAMD)</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AXT107 0.1 mg/eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AXT107 0.25 mg/eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AXT107 0.5 mg/eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXT107 0.1 mg</intervention_name>
    <description>Single intravitreal injection of AXT107 0.1 mg/eye (low dose)</description>
    <arm_group_label>Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXT107 0.25 mg</intervention_name>
    <description>Single intravitreal injection of AXT107 0.25 mg/eye (mid dose)</description>
    <arm_group_label>Mid Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXT107 0.5 mg</intervention_name>
    <description>Single intravitreal injection of AXT107 0.5 mg/eye (high dose)</description>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 50 years of age or older diagnosed in the study eye with subfoveal choroidal&#xD;
             neovascularization (CNV) or juxtafoveal CNV secondary to AMD&#xD;
&#xD;
          -  Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS)&#xD;
             letter score of 65 to 10 in the study eye&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study-related procedures&#xD;
&#xD;
          -  Provide signed inform consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Macular edema or CMV secondary to any causes other than AMD in the study eye&#xD;
&#xD;
          -  Previously-treated patients who are not responders to anti-VEGF&#xD;
&#xD;
          -  Any condition that may preclude improvement in visual acuity in the study eye&#xD;
&#xD;
          -  Previous vitreoretinal surgery, filtration surgery, and cataract surgery within 3&#xD;
             months in the study eye&#xD;
&#xD;
        Note: Other inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>CMO of AsclepiX</last_name>
    <phone>800-572-3545</phone>
    <email>info@asclepix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AsclepiX Investigative Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AsclepiX Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AsclepiX Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AsclepiX Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AsclepiX Investigative Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AsclepiX Investigative Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AsclepiX Investigative Site</name>
      <address>
        <city>Huntingdon Valley</city>
        <state>Pennsylvania</state>
        <zip>19006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AsclepiX Investigative Site</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AsclepiX Investigative Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AsclepiX Investigative Site</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AsclepiX</keyword>
  <keyword>Neovascular Age-Related Macular Degeneration</keyword>
  <keyword>nAMD</keyword>
  <keyword>eye diseases</keyword>
  <keyword>retinal diseases</keyword>
  <keyword>AXT107</keyword>
  <keyword>duration of action</keyword>
  <keyword>dose escalation</keyword>
  <keyword>macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

